Author(s)
Colombo D1, Simoni L2, Ori A2, Fiocchi M1, Frassi M3, Pagano Mariano G4, Fusaro E5, Lomater C6, Del Medico P7, Iannone F8, Foti R9, Limonta M10, Marchesoni A11, Raffeiner B12, Viapiana O13, Grassi W14, Grembiale RD15, Guggino G16, Faggioli P17, Tirri E18, Perricone R19, Sarzi Puttini PC20, De Vita S21, Conti F22, Zagni E1
1Novartis Farma S.p.A., Origgio, Italy, 2MediNeos Observational Research - IQVIA, Modena, Italy, 3ASST Spedali Civili, Brescia, Italy, 4Grande Ospedale Metropolitano, RC, RC, Italy, 5AOU Città della Salute e della Scienza, Turin, Italy, 6Ospedale Mauriziano Umberto I, Turin, Italy, 7Ospedale civile, Civitanova Marche, Italy, 8A.O.U. Policlinico Consorziale, Bari, Italy, 9A.O.U. Policlinico -Vittorio Emanuele, Catania, Italy, 10ASST Papa Giovanni XXIII, Bergamo, Italy, 11Istituto Ortopedico G. Pini, Milan, Italy, 12Ospedale Centrale di Bolzano, Bolzano, Italy, 13AOUI Verona Borgo Roma, Verona, Italy, 14Policlinico A. Murri, Jesi, Italy, 15A.O.U. Mater Domini, Catanzaro, Italy, 16A.O.U. Policlinico Giaccone, Palermo, Italy, 17Ospedale Civile di Legnano, Legnano, Italy, 18Ospedale San Giovanni Bosco, Naples, Italy, 19Policlinico Tor Vergata, Rome, Italy, 20ASST FBF Sacco, Milan, Italy, 21ASUIUD, Udine, Italy, 22Azienda Policlinico Umberto I, Rome, Italy
OBJECTIVES : Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy characterized by musculoskeletal signs/symptoms, joint pain and tenderness. A wide variety of pharmacologic treatments are available (nonsteroidal anti-inflammatories, corticosteroids, disease-modifying antirheumatic drugs including biologics). Scanty are the evidences of the efficacy of PsA treatments in the real-world. Results of an interim analysis of the Effectiveness of biologic treatments for psoriatic arthritis in Italy: an observational longitudinal study of real-life clinical practice (CHRONOS) study are here presented about 6-month response to biologics. Final results will be available by the end of Sept-2020. METHODS : CHRONOS is an observational retrospective and prospective cohort study; 410 PsA-diagnosed Italian adults starting a biologic between 6 and 24 months before enrolment were included. Primary objective was to assess the 6-month and 1-year response to biologics according to DAS28-EULAR criteria1. ACR20-50-70 responses and Health Assessment Questionnaire Disability Index (HAQ-DI) were evaluated too. RESULTS : Among 262 patients analysed, 147 (56.1%) were women, mean (SD) age and time from PsA diagnosis were 52.3 (11.8) and 8.2 (7.5) yrs respectively. Naïve to biologics were 127 (48.5%). During observation period (mean (SD): 15.7 (6.2) months) 223 (85.1%) and 32 (12.2%) patients assumed 1 and 2 subsequent biologics, respectively. Considering 174 patients with available DAS28-EULAR 6-month response, the most frequently administered biologics were secukinumab (65, 37.4%), adalimumab/biosimilar (30, 17.2%), etanercept/biosimilar (28, 16.1%) and certolizumab (21, 12.1%) and the 6-month response was good and moderate in 84 (48.3%) and 35 (20.1%) patients, respectively, while 55 (31.6%) patients were non-responders. ACR20, ACR50 and ACR70 6-month response, evaluated on 128 patients, was 45.3%, 31.3% and 18.8%, respectively. Mean (SD) HAQ-DI at therapy start was 1.01 (0.64) and 0.76 (0.63) after 6 months. CONCLUSIONS CHRONOS study preliminary results show a good 6-month DAS28-EULAR response to biologics in 48.3% of PsA patients in real-life setting. 1CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2005. S-93- S-99
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PBI57
Topic
Clinical Outcomes, Economic Evaluation, Health Service Delivery & Process of Care
Topic Subcategory
Clinical Outcomes Assessment, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Disease Management
Disease
Biologics and Biosimilars, Musculoskeletal Disorders